

Nicola Funel

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4802846/nicola-funel-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

87
papers

3,659
citations

31
h-index

59
g-index

91
ext. papers

4,206
ext. citations

6.4
avg, IF

4.56
L-index

#	Paper	IF	Citations
87	PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2622-9	2.2	368
86	MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. <i>Cancer Research</i> , 2010 , 70, 4528-38	10.1	361
85	Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. <i>Cancer Research</i> , 2006 , 66, 3928-35	10.1	276
84	Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. <i>PLoS ONE</i> , 2010 , 5, e10630	3.7	230
83	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. <i>Nature Genetics</i> , 2014 , 46, 994-1000	36.3	226
82	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. <i>Nature Genetics</i> , 2015 , 47, 911-6	36.3	171
81	MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression. <i>Gastroenterology</i> , 2014 , 146, 268-77.e18	13.3	125
80	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nature Communications</i> , 2018 , 9, 556	17.4	103
79	Italian consensus guidelines for the diagnostic work-up and follow-up of cystic pancreatic neoplasms. <i>Digestive and Liver Disease</i> , 2014 , 46, 479-93	3.3	90
78	microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 1389-404	7.5	80
77	Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 1735-46	6.1	73
76	Dextran-catechin conjugate: a potential treatment against the pancreatic ductal adenocarcinoma. <i>Pharmaceutical Research</i> , 2012 , 29, 2601-14	4.5	67
75	Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma. <i>Cancer Research</i> , 2013 , 73, 6745-56	10.1	65
74	TGF- β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. <i>Nature Communications</i> , 2018 , 9, 1845	17.4	61
73	High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. <i>PLoS ONE</i> , 2012 , 7, e49145	3.7	57
72	FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2016 , 22, 6987-7005	5.6	52
71	Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 9	22.4	48

70	TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. <i>International Journal of Cancer</i> , 2015 , 137, 2175-83	7.5	46
69	Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer. <i>Current Pharmaceutical Design</i> , 2013 , 19, 940-950	3.3	46
68	miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2014 , 33, 384-93	1.4	45
67	Contrast enhancement pattern on multidetector CT predicts malignancy in pancreatic endocrine tumours. <i>European Radiology</i> , 2015 , 25, 751-9	8	41
66	Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression. <i>Lancet, The</i> , 2015 , 385 Suppl 1, S37	4.0	41
65	Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/βcatenin signalling in pancreatic adenocarcinoma. <i>Oncotarget</i> , 2014 , 5, 5335-49	3.3	40
64	Robotic pancreatoduodenectomy with vascular resection. <i>Langenbeck's Archives of Surgery</i> , 2016 , 401, 1111-1122	3.4	39
63	Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt346	9.7	39
62	Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. <i>Scientific Reports</i> , 2017 , 7, 44686	4.9	36
61	Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. <i>Pharmacogenomics</i> , 2011 , 12, 1641-52	2.6	36
60	Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. <i>Digestive and Liver Disease</i> , 2013 , 45, 95-9	3.3	34
59	Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. <i>Cancers</i> , 2019 , 11,	6.6	33
58	Imidazo[2,1-b][1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2020 , 189, 112088	6.8	32
57	Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. <i>Biomatter</i> , 2014 , 4, e955386		32
56	Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. <i>Laboratory Investigation</i> , 2008 , 88, 773-84	5.9	29
55	Vascular dysfunction in a mouse model of Rett syndrome and effects of curcumin treatment. <i>PLoS ONE</i> , 2013 , 8, e64863	3.7	29
54	Magnetic carbon nanotubes: a new tool for shepherding mesenchymal stem cells by magnetic fields. <i>Nanomedicine</i> , 2011 , 6, 43-54	5.6	28
53	Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. <i>EBioMedicine</i> , 2019 , 39, 215-225	8.8	27

52	The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies. <i>Seminars in Cancer Biology</i> , 2020 , 60, 238-248	12.7	26
51	A Model of a Zebrafish Avatar for Co-Clinical Trials. <i>Cancers</i> , 2020 , 12,	6.6	24
50	Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2020 , 271, 1137-1147	7.8	23
49	3-(6-Phenylimidazo [2,1-][1,3,4]thiadiazol-2-yl)-1-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma. <i>Molecules</i> , 2020 , 25,	4.8	22
48	Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. <i>International Journal of Cancer</i> , 2019 , 144, 1275-1283	7.5	22
47	Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919841233	5.4	21
46	A propensity score-matched analysis of robotic versus open pancreatoduodenectomy for pancreatic cancer based on margin status. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019 , 33, 234-242	5.2	20
45	Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer. <i>Expert Review of Molecular Diagnostics</i> , 2011 , 11, 695-701	3.8	20
44	Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. <i>Current Pharmaceutical Design</i> , 2013 , 19, 940-50	3.3	20
43	AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients. <i>PLoS ONE</i> , 2014 , 9, e108057	3.7	19
42	Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 524-33	12.9	19
41	The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. <i>Pharmacogenomics</i> , 2019 , 20, 49-68	2.6	18
40	Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. <i>JCI Insight</i> , 2020 , 5,	9.9	17
39	MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy. <i>Clinical Epigenetics</i> , 2015 , 7, 129	7.7	16
38	Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. <i>Oncotarget</i> , 2016 , 7, 28556-69	3.3	16
37	Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells. <i>Current Drug Targets</i> , 2014 , 15, 1331-40	3	16
36	Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds. <i>British Journal of Cancer</i> , 2020 , 123, 644-656	8.7	15
35	Ukrain affects pancreas cancer cell phenotype in vitro by targeting MMP-9 and intra-/extracellular SPARC expression. <i>Pancreatology</i> , 2010 , 10, 545-52	3.8	14

34	Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. <i>Carcinogenesis</i> , 2016 , 37, 957-64	4.6	13
33	Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. <i>Carcinogenesis</i> , 2018 , 39, 360-367	4.6	12
32	Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. <i>World Journal of Gastroenterology</i> , 2020 , 26, 2792-2809	5.6	12
31	New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 1081-1090	3.8	12
30	SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. <i>Scientific Reports</i> , 2017 , 7, 43812	4.9	11
29	Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors. <i>Cancers</i> , 2019 , 11,	6.6	11
28	Loss of heterozygosity status of D9S105 marker is associated with downregulation of Krüppel-like factor 4 expression in pancreatic ductal adenocarcinoma and pancreatic intraepithelial lesions. <i>Pancreatology</i> , 2011 , 11, 30-42	3.8	11
27	Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of Vater carcinomas. <i>PLoS ONE</i> , 2010 , 5, e12653	3.7	11
26	Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. <i>Biochemical Pharmacology</i> , 2019 , 166, 128-138	6	9
25	A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. <i>Pharmacogenomics</i> , 2014 , 15, 609-18	2.6	9
24	Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors. <i>Scientific Reports</i> , 2016 , 6, 39565	4.9	9
23	Triticum vulgare extract exerts an anti-inflammatory action in two in vitro models of inflammation in microglial cells. <i>PLoS ONE</i> , 2018 , 13, e0197493	3.7	7
22	Anti-diabetic properties of a non-conventional radical scavenger, as compared to pioglitazone and exendin-4, in streptozotocin-nicotinamide diabetic mice. <i>European Journal of Pharmacology</i> , 2014 , 729, 37-44	5.3	6
21	Evaluation of vascular infiltration in resected patients for pancreatic cancer: comparison among multidetector CT, intraoperative findings and histopathology. <i>Abdominal Imaging</i> , 2007 , 32, 737-42		6
20	5Tnucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer. <i>Oncotarget</i> , 2018 , 9, 16437-16450	3.3	6
19	Lipoprotein glomerulopathy: first report of 2 not consanguineous Italian men from the same town. <i>Journal of Nephrology</i> , 2011 , 24, 381-5	4.8	6
18	Multidetector CT in the evaluation of retroperitoneal fat tissue infiltration in ductal adenocarcinoma of the pancreatic head: correlation with histopathological findings. <i>Abdominal Imaging</i> , 2010 , 35, 465-70		5
17	Myoclonus epilepsy, retinitis pigmentosa, leukoencephalopathy and cerebral calcifications associated with a novel m.5513G>A mutation in the MT-TW gene. <i>Biochemical and Biophysical Research Communications</i> , 2018 , 500, 158-162	3.4	4

16	Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer. <i>Anticancer Research</i> , 2019 , 39, 3609-3614	2.3	4
15	Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients. <i>Cancers</i> , 2021 , 13,	6.6	4
14	Silver Nanoparticle-Coated Polyhydroxyalkanoate Based Electrospun Fibers for Wound Dressing Applications. <i>Materials</i> , 2021 , 14,	3.5	4
13	Triticum vulgare Extract Modulates Protein-Kinase B and Matrix Metalloproteinases 9 Protein Expression in BV-2 Cells: Bioactivity on Inflammatory Pathway Associated with Molecular Mechanism Wound Healing. <i>Mediators of Inflammation</i> , 2020 , 2020, 2851949	4.3	3
12	Expression of SP7, RUNX1, DLX5, and CTNNB1 in human mesenchymal stem cells cultured on xenogeneic bone substitute as compared with machined titanium. <i>Implant Dentistry</i> , 2014 , 23, 407-15	2.4	3
11	The odd case of a small and mucinous-like acinar cell cystoadenocarcinoma of the pancreas. <i>Pancreatology</i> , 2012 , 12, 421-2	3.8	3
10	Robotic-assisted versus open left pancreatectomy for cystic tumours: A single-centre experience. <i>Journal of Minimal Access Surgery</i> , 2020 , 16, 66-70	1.2	3
9	The occurrence of prion protein in surgically resected pancreatic adenocarcinoma. <i>Pancreatology</i> , 2020 , 20, 1218-1225	3.8	3
8	Pancreatic cancer. <i>Gastroenterology Research and Practice</i> , 2015 , 2015, 809036	2	2
7	Pancreatic serous cystoadenoma (CSA) showing increased tracer uptake at 68-GaDOTA-peptide Positron Emission Tomography (68Ga-DOTA-peptide PET-CT): a case report. <i>BMC Surgery</i> , 2020 , 20, 331	2.3	2
6	Prognostic impact of conservative surgery for pancreatic IPMNs. <i>Surgical Oncology</i> , 2021 , 38, 101582	2.5	2
5	Pancreatoduodenectomy without Vascular Resection in Patients with Primary Resectable Adenocarcinoma and Unilateral Venous Contact: A Matched Case Study. <i>Gastroenterology Research and Practice</i> , 2018 , 2018, 1081494	2	1
4	Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 2342-2345	4	1
3	Detailing the ultrastructure's increase of prion protein in pancreatic adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2021 , 27, 7324-7339	5.6	0
2	The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Letter. <i>Clinical Cancer Research</i> , 2016 , 22, 2594	12.9	
1	Advances in Primary Cell Culture of Pancreatic Cancer 2014 , 11-38		